Implantable vs Prolonged External Electrocardiographic Monitoring for Atrial Fibrillation Detection in Patients With Ischemic Stroke

JAMA ◽  
2021 ◽  
Vol 326 (14) ◽  
pp. 1439
Author(s):  
Hiroshi Ito
JAMA ◽  
2021 ◽  
Vol 325 (21) ◽  
pp. 2160
Author(s):  
Brian H. Buck ◽  
Michael D. Hill ◽  
F. Russell Quinn ◽  
Ken S. Butcher ◽  
Bijoy K. Menon ◽  
...  

2018 ◽  
Vol 107 (10) ◽  
pp. 871-880 ◽  
Author(s):  
Karl Georg Haeusler ◽  
Klaus Gröschel ◽  
Martin Köhrmann ◽  
Stefan D. Anker ◽  
Johannes Brachmann ◽  
...  

2018 ◽  
Vol 13 (9) ◽  
pp. 893-904 ◽  
Author(s):  
Tommaso Sanna

An increasing number of detection tools are available and several detection strategies have been described to pursue the diagnosis of atrial fibrillation to prevent ischemic stroke. Monitoring tools include standard electrocardiography, snapshot single-lead recordings with professional or personal devices (e.g. smartphone-based), Holter monitor, external devices with long-term recording capabilities, and cardiac implantable electronic devices, including pacemakers, implantable cardioverter defibrillators and insertable cardiac monitors. Insertable cardiac monitors have shown high sensitivity and specificity for the detection of atrial fibrillation, allow up to three years of continuous monitoring, do not require cooperation of the patient, are well tolerated, have a short device-related time delay between detection of atrial fibrillation and notification to the physician, provide information on atrial fibrillation burden and are minimally invasive. On the other hand, insertable cardiac monitors require a considerable use of resources to process the recordings and have a significant initial cost. Studies conducted with insertable cardiac monitors on patients with prior stroke and on patients with risk factors for stroke but no prior cerebrovascular events or atrial fibrillation have consistently shown a measurable incidence of atrial fibrillation at follow-up. However, the effectiveness of oral anticoagulations in reducing the incidence of ischemic stroke in patients with atrial fibrillation lasting less than 24 h, though reasonable, is currently unproven. The future of atrial fibrillation detection tools and atrial fibrillation detection strategies will be influenced by ongoing studies exploring whether oral anticoagulations reduce the incidence of stroke in patients with atrial fibrillation burden lower than 24 h.


Circulation ◽  
2019 ◽  
Vol 140 (22) ◽  
pp. 1834-1850 ◽  
Author(s):  
Renate B. Schnabel ◽  
Karl Georg Haeusler ◽  
Jeffrey S. Healey ◽  
Ben Freedman ◽  
Giuseppe Boriani ◽  
...  

Cardiac thromboembolism attributed to atrial fibrillation (AF) is responsible for up to one-third of ischemic strokes. Stroke may be the first manifestation of previously undetected AF. Given the efficacy of oral anticoagulants in preventing AF-related ischemic strokes, strategies of searching for AF after a stroke using ECG monitoring followed by oral anticoagulation (OAC) treatment have been proposed to prevent recurrent cardioembolic strokes. This white paper by experts from the AF-SCREEN International Collaboration summarizes existing evidence and knowledge gaps on searching for AF after a stroke by using ECG monitoring. New AF can be detected by routine plus intensive ECG monitoring in approximately one-quarter of patients with ischemic stroke. It may be causal, a bystander, or neurogenically induced by the stroke. AF after a stroke is a risk factor for thromboembolism and a strong marker for atrial myopathy. After acute ischemic stroke, patients should undergo 72 hours of electrocardiographic monitoring to detect AF. The diagnosis requires an ECG of sufficient quality for confirmation by a health professional with ECG rhythm expertise. AF detection rate is a function of monitoring duration and quality of analysis, AF episode definition, interval from stroke to monitoring commencement, and patient characteristics including old age, certain ECG alterations, and stroke type. Markers of atrial myopathy (eg, imaging, atrial ectopy, natriuretic peptides) may increase AF yield from monitoring and could be used to guide patient selection for more intensive/prolonged poststroke ECG monitoring. Atrial myopathy without detected AF is not currently sufficient to initiate OAC. The concept of embolic stroke of unknown source is not proven to identify patients who have had a stroke benefitting from empiric OAC treatment. However, some embolic stroke of unknown source subgroups (eg, advanced age, atrial enlargement) might benefit more from non–vitamin K-dependent OAC therapy than aspirin. Fulfilling embolic stroke of unknown source criteria is an indication neither for empiric non–vitamin K-dependent OAC treatment nor for withholding prolonged ECG monitoring for AF. Clinically diagnosed AF after a stroke or a transient ischemic attack is associated with significantly increased risk of recurrent stroke or systemic embolism, in particular, with additional stroke risk factors, and requires OAC rather than antiplatelet therapy. The minimum subclinical AF duration required on ECG monitoring poststroke/transient ischemic attack to recommend OAC therapy is debated.


2015 ◽  
Vol 8 (2) ◽  
pp. 263-269 ◽  
Author(s):  
Charles Dussault ◽  
Hadi Toeg ◽  
Meena Nathan ◽  
Zhi Jian Wang ◽  
Jean-Francois Roux ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document